Appendix Table F4, Standard treatment study risk of bias - Early Diagnosis, Prevention, and Treatment of Clostridium difficile: Update

Warning: The NCBI web site requires JavaScript to function. more...

Study ID	Design	Funding source	Overall Summary	Comments
Johnson, 2014³⁷	RCT- 3 arms, tolevamer vs.metronidazole vs. vancomycin	Genzyme (tolevamer maker)	Low risk of bias	No reason to downgrade.
Cornely, 2012³⁸	RCT- Vancomycin vs. fidaxomicin	Optimer pharmaceutical (fidaxomicin maker)	Low risk of bias	No reason to downgrade.
Wenisch, 2012³⁹	Prospective Cohort – oral metronidazole vs. IV metronidazole vs. oral vancomycin	“No financial support was received for this study”	High risk of bias	Downgraded for: “no” answers to sequence generation, allocation concealment, blinding, and other (non-RCT). Unclear for incomplete outcome data

Early Diagnosis, Prevention, and Treatment of Clostridium difficile: Update [Internet].

Comparative Effectiveness Reviews, No. 172.

Butler M, Olson A, Drekonja D, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.